RDx BioScience Points to Physician Gap in Addiction Medicine, Urges More Physicians to Specialize in Treatment of Substance-Use Disorders

KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/addiction?src=hash” target=”_blank”gt;#addictionlt;/agt;–In response to the U.S. surgeon general’s estimate
that more than 20 million
 people have a substance-use disorder, RDx
BioScience (RDx)
highlights the urgent need for physicians with
extensive clinical experience to specialize in addiction medicine to
improve treatment and fill a gap in care to address the nation’s growing
drug overdose crisis.

“The opioid
epidemic
has underscored the impact of the physician shortage in
this area, prompting medical institutions across the United States to
create fellowships for physicians interested in treating substance-use
disorders,” says Scott Howell, D.O., MPH &TM, CPE, chief medical
officer, RDx. “Substance-use disorders must be treated with the same
precision and science as other diseases, which is why RDx offers
expertise in drug testing in addiction treatment settings. We provide a
collaborative relationship and a high-quality lab for test panel
selection, detecting sample tampering, interpreting test results, and
regional drug use trends.”

In the past, addiction medicine has been the purview of psychiatry, but
in 2015 the American Board of Medical Specialties (ACGME) began recognizing
addiction medicine
as a legitimate subspecialty, paving the way for
physician training in this field. In 2018, ACGME began accrediting its
first round of addiction medicine fellowship programs. Physicians can
also turn to specialists to learn, for example, how to provide medication-assisted
treatment like 
buprenorphine, which has been shown to reduce
the risk of death 
among people who have recovered from an
opioid overdose.

“Addiction treatment is a unique medical specialty, different than
practices that focus on infectious or short-term disease, and it
requires treatment programs and exceptional laboratory services to
effectively address the nature of addiction and the needs of those who
battle the opioid epidemic,” Howell adds, “RDx is committed to playing a
role in helping individuals recover from drug abuse by directing the
delivery of patient care using a high-technology laboratory to provide
full-service diagnostics and genomic testing supported by evidence-based
research.”

About RDx BioScience

RDx is a full-service, high-technology laboratory. We are fast,
accurate, and deliver value-based service nationally. RDx is accredited
by the College
of American Pathologists (CAP)
 as a certified, full-service medical
laboratory. Visit http://www.rdxbioscience.com/

Contacts

Media:
CPR for RDx
Brittany Tedesco
btedesco@cpronline.com
201.641.1911 x14